NRXP, GOING FOR THE GOLD??? ——— NRx Pharmaceuticals Announces New Finding from ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19
The Real Value Of A Breakthrough Therapy Designation
Summary
——— Average approval time reduced by 2.5-3.5 years. ——— Breakthrough therapy designation usually increases valuation significantly. ——— Takeover offers typically increase with breakthrough therapy designations. ——— Takeover offers for a company with 2 breakthrough therapy designations increase significantly and quickly. ——— Evaluating high flyers and value companies.
How does the FDA turn down incomplete data every page they turn. This is fourth request...his game is stall stall stall and look behind door number #2 ....come on penny! The guy posts on message boards!!!! You know, That says it all....